BIIB vs VNDA
BIIB: Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease. VNDA: Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in dermatology, rare diseases, and oncology.
Side-by-side fundamentals
| Metric | BIIB | VNDA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $197.74 | $5.35 | |
| Market cap as of 2026-07-23 | $29.8B | $329M | |
| P/E as of 2026-07-23 | 21.75 | n/a | |
| PEG as of 2026-07-23 | 10.24 | -0.00 | VNDA lower |
| Net margin as of 2026-07-23 | +13.8% | -110.0% | BIIB higher |
| Gross margin as of 2026-07-23 | +75.5% | +94.2% | VNDA higher |
| Operating margin as of 2026-07-23 | +17.5% | -73.6% | BIIB higher |
| ROE as of 2026-07-23 | +7.5% | -61.4% | BIIB higher |
| ROA as of 2026-07-23 | +4.7% | -44.6% | BIIB higher |
| Debt / equity as of 2026-07-23 | 0.34 | 0.03 | VNDA lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.2% | +8.2% | VNDA higher |
| Revenue CAGR (3y) SEC XBRL | -0.9% | -5.3% | BIIB higher |
| Beta as of 2026-07-23 | 0.16 | 0.62 | |
| 1-year return as of 2026-07-22 close | +54.7% | +13.6% | BIIB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.